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Background
Interaction between M.avium a n dH I Vd r u g si su n a -
voidable in HIV patients as for an improved life expec-
tancy of HIV patients, additional medications have to be
administered along with HIV drugs. The anti-M.avium
drug rifabutin and protease inhibitor, ritonavir are asso-
ciated with significant drug interactions involving the
cytochrome P450 (CYP) enzyme system. Little informa-
tion is available on the role of various drug delivery stra-
tegies in alleviations of interactions between anti-M.
avium and anti-HIV drugs. The purpose of the present
study was to evaluate effect of encapsulation of rifabutin
and ritonavir in PLGA nanoparticles on the already
known drug interaction exhibited by these drugs.
Methods
This study was designed including administration of
rifabutin and ritonavir singly and in combination in free
and nanoencapsulated form to swiss albino mice. Blood
samples were taken following drug administration at
various time intervals and pharmacokinetic parameters
were assessed as: area under plasma drug concentration
over time curve (AUC0-∞), mean residence time (MRT)
and Cmax etc.
Results
Overall, nanoencapsulation was observed to avoid the
known adverse drug interactions between RBT and RTV
in the drug interaction study. (p-value<0.001).
Conclusion
Our results clearly emphasize the potential of the PLGA
nanoparticle formulation to minimize drug interactions
as the encapsulated drugs did not result in any signifi-
cant alteration in kinetic parameters upon co-adminis-
tration. It can be reasonably stated that nano-
encapsulation would not only permit intermittent dosing
but also a more favorable pharmacokinetics which
further can overcome the drug interactions.
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